The Nvidia Killer is Here
Sponsored
Artificial intelligence could have already made you a millionaire… Because back in 2013, researchers from Stanford University built the “world's largest virtual brain” with Nvidia chips. This single event marked the beginning of the chipmaker's reign as the “King of AI.” You could've raked in 12,035% gains had you bought Nvidia shares when this story became public. That's enough to turn a $9,000 stake into more than $1 million. But there's no reason to beat yourself up for missing out on this life-changing opportunity. Today you have a second shot at six- or even seven-figure gains. Because there's a new player in town… One that's set to dethrone Nvidia. This off-the-radar company from California is about to release an AI chip that's superior to Nvidia's technology. I'm talking about a 100x performance boost. Access to this kind of chip is still highly restricted. The U.S. Air Force is one elite client that was allowed to use it early. But soon it will be available to the mainstream. And if you position yourself BEFORE this chip reaches the mass market, you could turn every $1 into $120… Just like early Nvidia investors did. I just published a brand-new presentation on this unique opportunity. Access is instant and free. Get the full story here while there's still time.
Medtronic (MDT), a titan in the biotech realm, has not just been making waves but causing tsunamis with its stellar financial performances and groundbreaking strategic leaps forward.
And it just crushed its most recent earnings report.
As we pull back the curtain on this industry behemoth, we uncover a tapestry of innovation, resilience, and ambition.
Dive with us into this report, where we unravel all the reasons that make Medtronic not just an attractive investment but a thrilling voyage into the future of biotech.
Key Financial Highlights
Revenue Growth: Medtronic reported a Q1 worldwide revenue of $7.702 billion, marking a 4.5% increase as reported and a 6.0% organic growth. This growth reflects the company's strength across various businesses and geographies, underpinned by innovation and robust underlying fundamentals.
Earnings Per Share (EPS): While the GAAP diluted EPS of $0.59 saw a 16% decrease, the non-GAAP diluted EPS of $1.20 increased by 6%. This growth, despite the unfavorable impact from foreign currency translation, indicates the company's ability to maintain profitability.
Guidance for FY24: Medtronic has raised its FY24 organic revenue growth guidance to 4.5% and increased its non-GAAP EPS guidance range to $5.08 to $5.16, reflecting confidence in its future performance.
Operational Highlights
Product Launches: Medtronic has commenced U.S. launches of the MiniMed™ 780G system with Guardian™ 4 sensor in the Diabetes segment and the Micra™ AV2 and Micra™ VR2 leadless pacemakers in the Cardiovascular segment. These launches signify the company's commitment to innovation and addressing patient needs.
Cardiovascular Portfolio: This segment saw a revenue of $2.850 billion, a 5.5% increase as reported, driven by growth in Defibrillation Solutions, Cardiovascular Diagnostics, and Cardiac Pacing Therapies.
Neuroscience Portfolio: With a revenue of $2.219 billion, this segment witnessed growth in Spine & Biologics, ENT, and Brain Modulation, highlighting the company's diversified strength.
Medical Surgical Portfolio: Reporting a revenue of $2.039 billion, this segment saw growth in Advanced Surgical Technologies and Patient Monitoring, emphasizing the company's broad-based capabilities.
Diabetes: The Diabetes segment reported a revenue of $578 million, a 6.8% increase, driven by the MiniMed™ 780G system's adoption and the strength of the Guardian™ 4 sensor.
Management's Perspective: Geoff Martha, Medtronic's chairman and CEO, expressed satisfaction with the company's strong start to the fiscal year, emphasizing the broad-based results across all segments. The company's focus on transformation aims to ensure sustainable growth and maximize shareholder value.
Conclusion
Medtronic's recent financial results, combined with its strategic advancements and management's optimistic outlook, make it a promising biotech stock for potential investors. The company's commitment to innovation, its diversified portfolio, and its ability to navigate challenges position it well for future growth. Investors seeking a robust biotech stock with a proven track record and a bright future should consider Medtronic plc as a top contender.
NASA and Bill Gates are ALL IN on this new technology
Sponsored
Elon Musk's rival space-faring company, NASA, just partnered up with this little known company… Why? Because this tiny company holds the key to a $7 Trillion Dollar revolution. Most mainstream investors have no idea this $7 Trillion Revolution is taking place… But while everyone else is distracted by AI, this new phenomenon is quietly taking the tech world by storm… Companies like Google, Intel, and Microsoft are SCRAMBLING to get ahead of it… Even Bill Gates is ALL-IN on this new innovation… “…It's as revolutionary as the personal computer, the Internet, and the mobile phone.” It's no wonder why NASA decided to partner up with the leading company in this silent revolution… >>Click here to discover the innovation that has NASA and Bill Gates so excited.
